What is Experic?
Experic operates as a critical partner in the pharmaceutical life cycle, providing end-to-end support from initial product conception through to clinical and commercial scale manufacturing. The company distinguishes itself through a state-of-the-art, Class A cGMP facility capable of handling diverse dosing and packaging formats, including tablets, pellets, capsules, and specialized low-dose dry powder inhalation. By integrating advanced manufacturing capabilities with rigorous quality control, Experic addresses the complex logistical and technical challenges inherent in global pharmaceutical supply chains. Their service model is designed to accommodate expedited project timelines, ensuring that clients maintain continuity from early-stage development to full-scale market distribution.
The company's operational framework is built upon deep technical expertise, allowing it to navigate the stringent regulatory requirements of the pharmaceutical industry. By positioning itself as a versatile CDMO, Experic serves as a vital link for biopharmaceutical firms seeking to outsource complex manufacturing processes without compromising on quality or speed-to-market.
How much funding has Experic raised?
Experic has raised a total of $14.2M across 2 funding rounds:
Debt
$150K
Series B
$14M
Debt (2020): $150K with participation from PPP
Series B (2022): $14M led by East Seattle Partners and Harro Höfliger
Key Investors in Experic
East Seattle Partners
East Seattle Partners is a multi-asset investment firm specializing in growth equity and real estate, focusing on companies that aim to redefine business categories and address significant market challenges.
Harro Höfliger
Harro Höfliger is a global leader in the development and production of customer-specific production and packaging systems for the pharmaceutical and medical device industries.
PPP
Public-Private Partnership
What's next for Experic?
With the recent infusion of capital, Experic is well-positioned to accelerate its growth strategy within the competitive CDMO landscape. The company is expected to leverage these resources to further optimize its cGMP facility, potentially expanding its capacity for high-demand packaging formats and inhalation technologies. As the pharmaceutical sector continues to prioritize supply chain resilience and specialized manufacturing, Experic's focus on providing high-quality, scalable solutions will likely attract further strategic partnerships. Future initiatives will likely center on deepening its service offerings to support increasingly complex drug delivery systems, thereby cementing its role as a cornerstone of the pharmaceutical manufacturing ecosystem.
See full Experic company page
